Focusing on those activity profiles representing actionable perturbations and predicting endocrine resistance in ER+ breast cancer, we identify a 31-gene AKT signaling module, which also predicts sensitivity to AKT/PI3K/mTOR inhibitors [16,17], thus providing a means of identifying ER+ patients who could potentially benefit from such treatment. This evidence concerns the gene AKT1 and breast carcinoma.